ERBB2 and breast carcinoma: In recent years, enormous progress of neoadjuvant therapy has been achieved in HER2-positive breast cancer, which mainly includes two aspects: (1) the use of dual-targeted regimen; (2) the combination of chemotherapeutic agents and targeted agents [4,5,6,7,8].